Compare MX & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MX | ACET |
|---|---|---|
| Founded | 2003 | 1947 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.4M | 77.3M |
| IPO Year | 2007 | 2017 |
| Metric | MX | ACET |
|---|---|---|
| Price | $3.49 | $8.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $5.75 | ★ $48.33 |
| AVG Volume (30 Days) | ★ 297.1K | 141.6K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.06 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $178,860,000.00 | N/A |
| Revenue This Year | $8.55 | N/A |
| Revenue Next Year | $6.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.18 | $0.46 |
| 52 Week High | $4.50 | $9.05 |
| Indicator | MX | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 74.73 | 60.07 |
| Support Level | $2.69 | $7.70 |
| Resistance Level | $4.50 | $8.34 |
| Average True Range (ATR) | 0.12 | 0.49 |
| MACD | 0.06 | 0.20 |
| Stochastic Oscillator | 91.07 | 74.45 |
MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The company operates in two segments namely, Transitional Fab 3 foundry services and Standard products business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).